Abstract
dc:description.abstract<p>Cigarette smoking is prevalent in HIV-infected people, resulting in higher mortality rate and more premature heart and lung diseases in the highly active antiretroviral therapy era. Smoking is a modifiable risk factor for these adverse outcomes and smoking cessation in HIV-positive smokers is feasible, although further efforts are needed to improve smoking cessation programs in HIV-positive persons.</p> <p>In this thesis, I examined the role of smoking in mortality and morbidity in HIV-positive Ontarians, and piloted a smoking cessation program featuring a novel smoking cessation aid, varenicline, in HIV-infected smokers. In addition, I explored three different methods to resolve missing data, by excluding, grouping and multiply imputing missing data. I adopted three different study designs in my thesis studies: retrospective cohort, cross-sectional and open label study.</p> <p>We found smoking prevalence in HIV-infected people was consistently higher than in the general population. Smoking was associated with a higher risk of death, of respiratory symptoms, hospitalization and chronic obstructive pulmonary disease, and with reduced lung function and less CD4-T-lymphocyte improvement over time. We found varenicline was as effective in HIV-positive smokers as in non-HIV smokers reported by previous studies.</p>
Degree
thesis:*- Department dc:contributor.department
- Health Research Methodology
- Year dc:date.issued
- 2011
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Cui, Qu
- Advisors dc:contributor.advisor
-
- Smieja, Marek Jozef
- Thabane, Lehana
- Andrew McIvor, Fiona Smaill
Subjects
dc:subject × 7Identifiers
dc:identifier.*- Identifier URI
- https://doi.org/10.71548/18671
- Dc Identifier Other
-
opendissertations/6156
7161
2231208